SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cambridge Antibody Technology Group

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jongmans who started this subject9/18/2000 1:51:06 PM
From: nigel bates  Read Replies (1) of 625
 
Anyone noticed this on one of the Humab threads? (& if you're capable of more informed comment than I am, please share...) -

Message 14403402
"...Söderlind and his colleagues have developed a technology that allows them to vary all six CDRs of an antibody simultaneously into one single antibody framework. The result is a much larger range of potential recombinations, yielding antibody libraries with high genetic diversity--and since all of them originate from the human immune system, the potential for an immune reaction is minimal...."

Reference: "Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries," E Söderlind, L Strandbert, P Jirholt, N Kobayashi, V Alexeiva, A-M Åberg, A Nilsson, B Jansson, M Ohlin, C Wingren, L Danielsson, R Carlsson & CAK Borrebaeck, Nature Biotechnology, vol. 18, no. 8, p. 852-856.
An abstract of this article can be viewed at: nature.com journal/v18/n8/abs/nbt0800_852.html
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext